Fidelity Investments’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-275,758
| Closed | -$9.34M | – | 5540 |
|
|
2025
Q4 | $9.34M | Buy |
275,758
+27,380
| +11% | +$850K | ﹤0.01% | 2053 |
|
|
2025
Q3 | $6.41M | Buy |
248,378
+246,442
| +12,729% | +$3.23M | ﹤0.01% | 2156 |
|
|
2025
Q2 | $15.5K | Sell |
1,936
-2,024
| -51% | -$15.4K | ﹤0.01% | 4382 |
|
|
2025
Q1 | $38.6K | Sell |
3,960
-650,171
| -99% | -$6.39M | ﹤0.01% | 3971 |
|
|
2024
Q4 | $8.27M | Sell |
654,131
-309
| -0% | -$3.92K | ﹤0.01% | 2002 |
|
|
2024
Q3 | $10.5M | Hold |
654,440
| – | – | ﹤0.01% | 1903 |
|
|
2024
Q2 | $16M | Buy |
654,440
+1,983
| +0.3% | +$91.6K | ﹤0.01% | 1724 |
|
|
2024
Q1 | $46.9M | Buy |
652,457
+172,034
| +36% | +$23.9M | ﹤0.01% | 1350 |
|
|
2023
Q4 | $95.5M | Sell |
480,423
-81,989
| -15% | -$10.1M | 0.01% | 1034 |
|
|
2023
Q3 | $74.8M | Buy |
562,412
+38,601
| +7% | +$6.3M | 0.01% | 1092 |
|
|
2023
Q2 | $78.4M | Sell |
523,811
-33,169
| -6% | -$5.17M | 0.01% | 1094 |
|
|
2023
Q1 | $81.8M | Buy |
556,980
+187,953
| +51% | +$38M | 0.01% | 1059 |
|
|
2022
Q4 | $58.5M | Sell |
369,027
-78,051
| -17% | -$12.5M | 0.01% | 1191 |
|
|
2022
Q3 | $86.1M | Sell |
447,078
-64,943
| -13% | -$12.3M | 0.01% | 1012 |
|
|
2022
Q2 | $74.8M | Buy |
512,021
+114,183
| +29% | +$15.2M | 0.01% | 1083 |
|
|
2022
Q1 | $70M | Buy |
397,838
+116,734
| +42% | +$22M | 0.01% | 1253 |
|
|
2021
Q4 | $82.6M | Buy |
281,104
+138,463
| +97% | +$37M | 0.01% | 1193 |
|
|
2021
Q3 | $35.4M | Buy |
+142,641
| New | +$37.7M | ﹤0.01% | 1568 |
|
Fidelity Investments's RAPT Position: Q1 2026 in Review
Fidelity Investments sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 275,758 shares — an estimated $9.34M sold.
Fidelity Investments first reported a position in RAPT in Q3 2021 and held it in 18 quarters. The position peaked at $95.5M in Q4 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Fidelity Investments reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Fidelity Investments sold 275,758 RAPT Therapeutics shares in Q1 2026, an estimated $9.34M.
- Fidelity Investments first reported a position in RAPT Therapeutics in Q3 2021 and held it in 18 quarters.
- Fidelity Investments's RAPT Therapeutics position peaked at $95.5M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.